1945 Approval of drugs which may be used by certain optometrists

Approval of Drugs which may be Used by Certain Optometrists

[33 Pa.B. 4982]

   Under the Optometric Practice and Licensure Act (act) (63 P. S. §§ 244.1--244.12), and specifically as the act was amended by the act of December 16, 2002 (P. L. 1950, No. 225) (Act 225), the Secretary of Health (Secretary) has the authority to approve drugs for use in the practice of optometry as the ''practice of optometry'' is defined in the act. The State Board of Optometry, through the Secretary of State, provided the Secretary with a list of drugs on July 11, 2003, and requested that the Secretary approve the use of those drugs. Act 225 requires that the Secretary, within 90 days of the receipt of the list of drugs, and in consultation with the Physician General, approve or disapprove for good cause each drug. The Secretary has found good cause to approve the use of the following drugs in the practice of optometry:

Topical solutions:

moxifloxacin
gatifloxacin
cyclosporine ophthalmic emulsion

   Topical solutions and products only, not oral or injectable formulations.

   The approval of the use of these drugs is effective upon publication of this notice in the Pennsylvania Bulletin.

   Questions regarding this notice should be directed to John C. Hair, Director, Bureau of Community Program Licensure and Certification, 132 Kline Plaza, Suite A, Harrisburg, PA 17104, [phone].

   Persons with a disability who require an alternative format of this notice (that is, large print, audiotape or Braille) should contact John C. Hair at the number or address listed previously or for speech and/or hearingimpaired persons, V/TT [phone] or the Pennsylvania AT&T Relay Services at [phone] (TT).

CALVIN B. JOHNSON, M.D., M.P.H.,   
Secretary

[Pa.B. Doc. No. 03-1945. Filed for public inspection October 3, 2003, 9:00 a.m.]